Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

marketbeat.com - Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN
Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN
MarketBeat

Privium Fund Management B.V. lifted its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 82.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,622…

marketbeat.com - Ascendis Pharma A/S $ASND Stock Position Trimmed by New York State Common Retirement Fund
Ascendis Pharma A/S $ASND Stock Position Trimmed by New York State Common Retirement Fund
MarketBeat

New York State Common Retirement Fund lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 169,894 shares of the…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High - Should You Buy?
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High - Should You Buy?
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report)'s stock price hit a new 52-week high during trading on Friday. The stock traded as high as $41.72 and last traded at $41.68, with a volume of 3464713 shares changing hands. The stock had previously…

thehindubusinessline.com - Team BL - Q3 Results 31st Jan Live: Sun Pharma, GAIL India, IDFC First Bank, Birla Corporation, Zen Technologies, Bharat Dynamics, Delhivery, Fujiyama Power Systems to announce Q3 results
Q3 Results 31st Jan Live: Sun Pharma, GAIL India, IDFC First Bank, Birla Corporation, Zen Technologies, Bharat Dynamics, Delhivery, Fujiyama Power Systems to announce Q3 results
BusinessLine

Q3 Results Today, 31st Jan 2026 Live Updates: Find all the latest Q3 results 2026 updates of Sun Pharmaceutical Industries, GAIL India, IDFC First Bank, Bharat Dynamics, Delhivery, Central Depository Services, AFFLE 3I, Vinati Organics, R R Kabel…

newsbytesapp.com - Dwaipayan Roy - Sun Pharma's Q3 results: Net profit rises 16% to ₹3,369cr
Sun Pharma's Q3 results: Net profit rises 16% to ₹3,369cr
NewsBytes

What's the story Sun Pharma has reported a consolidated net profit of ₹3,369 crore for the December quarter. The figure marks a 16% growth from the ₹2,903 crore posted in the same period last year. The Mumbai-based drugmaker also…

thehindu.com - V. Swathi - TGPCB calls AQI by third party apps 'false'; says they use U.S. standards on Indian data
TGPCB calls AQI by third party apps 'false'; says they use U.S. standards on Indian data
The Hindu

The furore about rising pollution levels in the city notwithstanding, the environment regulatory authorities at State and Centre prefer to muddy up the issue. This became evident on Thursday at a conference on ‘Air pollution index and air…

cnbc.com - Michelle Fox - This dividend fund is one of Morningstar's best for 2026. Here are its manager's top stock picks
This dividend fund is one of Morningstar's best for 2026. Here are its manager's top stock picks
CNBC

Michael Barclay is all about consistency. As the lead portfolio manager of the Columbia Dividend Income Fund (LBSAX), he looks to not just grab yield, but produce the best-risk adjusted returns for its investors. By minimizing volatility, he can…

seekingalpha.com - Petri Dish Reports - Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal (NASDAQ:SGMT)
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal (NASDAQ:SGMT)
Seeking Alpha

Sagimet Biosciences dropped 9% after Ascletis Pharma's Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT's Denifanstat, a first-in-class FASN inhibitor, has multiple applications—acne…

indianexpress.com - Shoumitro Chatterjee - Signing of FTAs is a start. Their success will be judged by gains in global market
Signing of FTAs is a start. Their success will be judged by gains in global market
The Indian Express

These agreements also change how global firms view India. By signalling policy stability, they make long-term investment decisions more viable for companies seeking alternatives to China. Manufacturing in India for European markets makes commercial…

sciencedaily.com - Breakthrough sepsis drug shows promise in human trial
Breakthrough sepsis drug shows promise in human trial
ScienceDaily

Date: January 30, 2026 Source: Summary: A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a dangerous…

axios.com - Caitlin Owens - China threatens U.S.' drug-making crown amid Trump admin's research overhaul
China threatens U.S.' drug-making crown amid Trump admin's research overhaul
Axios

China has gotten very good at making cutting-edge pharmaceuticals — good enough to seriously threaten America's long-standing dominance in drug-making. Why it matters: This is all happening in plain sight. But it's playing out against a…

newsweek.com - Matthew Tostevin - U.S. allies make dangerous bet on China over Trump
U.S. allies make dangerous bet on China over Trump
Newsweek

British Prime Minister Keir Starmer's mission to China this week earned a five percent reduction in tariffs on scotch whisky exports and a stiff warning from U.S. President Donald Trump. 'Very dangerous,' was the way Trump put it. But Starmer was…

theonion.com - The Onion Staff - RFK Jr. Demonstrates How To Remove Tapeworm By Scooting Ass Across Carpet
RFK Jr. Demonstrates How To Remove Tapeworm By Scooting Ass Across Carpet
The Onion

WASHINGTON—In an address touting the practice as a completely drug-free method to relieve the common affliction, Secretary of Health and Human Services Robert F. Kennedy Jr. demonstrated Thursday how to remove a tapeworm by scooting one's…

nationalpost.com - Tracy Moran - Big revenue, trade leverage, and industrial perks: Why Trump's $264B tariff haul will be hard to give up
Big revenue, trade leverage, and industrial perks: Why Trump's $264B tariff haul will be hard to give up
National Post

WASHINGTON, D.C. — “‘Tariffs' is the most beautiful word to me in the dictionary,” President Donald Trump liked to say early last year, calling it his favourite word and promising they would help usher in a new…

cnbc.com - Michael Bloom - Here are Friday's biggest analyst calls: Nvidia, Apple, Tesla, Spotify, Broadcom, Southwest, AMD & more
Here are Friday's biggest analyst calls: Nvidia, Apple, Tesla, Spotify, Broadcom, Southwest, AMD & more
CNBC

Here are the biggest calls on Wall Street on Friday: Guggenheim upgrades GE Vernova to buy from neutral Guggenheim says it likes the company's cash generation. 'We are returning to a Buy rating (from Neutral) for GEV, and establishing a price…

Receive a Daily briefing on Pharma Industry News

Get Started